Hematology · Myeloproliferative NeoplasmsTrial Updateclinicalmid-term

Phase I Trial of Pacritinib with Venetoclax and Azacitidine for Myeloproliferative Neoplasms

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/2/2026, 6:30:49 AM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase I trial of pacritinib in combination with venetoclax and azacitidine could significantly impact treatment options for patients with accelerated and blast phase myeloproliferative neoplasms. Success in this trial may enhance Roswell Park's competitive positioning and influence market dynamics in this therapeutic area. Regulatory context from FDA (FDA AP — AZACITIDINE (SUPPL)) supports the near-term read. Assessment grounded in 12 ranked evidence items (4 high-relevance).

Strategic Assessment

Success in this trial may enhance Roswell Park's portfolio and provide a new combination therapy for MPN-AP/BP, impacting market dynamics. The strongest clinical anchor is Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms (ClinicalTrials.gov), entity match (pacritinib). In Hematology · Myeloproliferative Neoplasms, 3 regulatory and 1 competitive items passed relevance filtering for Pacritinib.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). This trial could position pacritinib as a viable treatment option in a competitive landscape dominated by existing therapies for MPN-AP/BP.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — AZACITIDINE (SUPPL) (FDA). Entity match (azacitidine). Positive trial outcomes could lead to new regulatory filings, impacting approval timelines and market entry for this combination therapy.

Key Risks

Elevated medium regulatory exposure for Pacritinib could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates safety and efficacy, it could lead to a new combination therapy that may capture market share from existing treatments, potentially increasing revenue for Roswell Park and associated stakeholders.
Upside for Pacritinib may improve if Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Pacritinib may improve if Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial may enhance Roswell Park's portfolio and provide a new combination therapy for MPN-AP/BP, impacting market dynamics.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy, as well as potential regulatory filings based on outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — AZACITIDINE (SUPPL)
FDAhigh relevance
Entity match (azacitidine)
FDA document
View source
FDA AP — VENETOCLAX (ORIG)
FDAhigh relevance
Entity match (venetoclax)
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govhigh relevance
Entity match (pacritinib)
FDA document
View source
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
ClinicalTrials.govhigh relevance
Entity match (azacitidine)
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pacritinib
Venetoclax
Azacitidine
Roswell Park Cancer Institute

Commercial impact

medium

If the trial demonstrates safety and efficacy, it could lead to a new combination therapy that may capture market share from existing treatments, potentially increasing revenue for Roswell Park and associated stakeholders.

Regulatory impact

medium

Positive trial outcomes could lead to new regulatory filings, impacting approval timelines and market entry for this combination therapy.

What to watch

Monitor trial results for safety and efficacy, as well as potential regulatory filings based on outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.